Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from the multicenter retrospective ReTrITa study.

被引：0
|
作者：
Signorelli, Carlo
Calegari, Maria Alessandra
Passardi, Alessandro
Lucchetti, Jessica
Zurlo, Ina Valeria
Morelli, Cristina
Dell'Aquila, Emanuela
Gemma, Donatello
Emiliani, Alessandra
Arrivi, Giulia
Zoratto, Federica
Chilelli, Mario Giovanni
Morandi, Maria Grazia
Santamaria, Fiorenza
Dettori, Manuela
Cosimati, Antonella
Saltarelli, Rosa
Minelli, Alessandro
Lucci-Cordisco, Emanuela
Basso, Michele
机构：
[1] ASL Viterbo, Belcolle Hosp, Med Oncol Unit, Viterbo, Italy
[2] Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, Oncol Med, IRCCS, Rome, Italy
[3] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Dept Med Oncol, Meldola, Italy
[4] Policlin Univ, Div Med Oncol, Campus Biomed, Rome, Italy
[5] Vito Fazzi Hosp, Med Oncol, Lecce, Italy
[6] Tor Vergata Univ Hosp, Dept Syst Med, Med Oncol Unit, Rome, Italy
[7] IRCCS Regina Elena Natl Canc Inst, Rome, Italy
[8] ASL Frosinone, Med Oncol Unit, Sora, Italy
[9] Isola Tiberina Hosp, Med Oncol, Gemelli Isola, Rome, Italy
[10] Sapienza Univ Rome, St Andrea Univ Hosp, Dept Clin & Mol Med, Oncol Unit, Rome, Italy
[11] ASL Latina, Osped St Maria Goretti, UOC Oncol, Latina, Italy
[12] ASL Rieti, San Camillo Lellis Hosp, Med Oncol Unit, Rieti, Italy
[13] Sapienza Univ Rome, Dept Expt Med, UOC Oncol A, Policlin Umberto I Expt Med,Network Oncol & Precis, Rome, Italy
[14] Osped Oncol Armando Businco, Med Oncol Dept, Cagliari, Italy
[15] UO Oncol Universitaria Casa Salute Aprilia, Med Oncol Dept, Aprilia, Italy
[16] San Giovanni Evangelista Hosp, UOC Oncol, ASL RM5, Tivoli, Italy
[17] Osped San Paolo, Med Oncol Dept, UO Oncol, ASL RM4, Civitavecchia, RM, Italy
[18] Fdn Policlin Univ Agostino Gemelli, Dipartimento Sci V & San Pubbl, UOC Genet Med, IRCCS, Rome, Italy
[19] Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, Med Oncol Dept, IRCCS, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.67
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [1] Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Narita, Yukiya
    Tsushima, Takahiro
    Ishihara, Makoto
    Todaka, Akiko
    Tanaka, Tsutomu
    Yokota, Tomoya
    Kadowaki, Shigenori
    Machida, Nozomu
    Ura, Takashi
    Fukutomi, Akira
    Ando, Masashi
    Onozawa, Yusuke
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Mori, Keita
    Yamazaki, Kentaro
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E15 - E22
  • [2] Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective "ReTrITA" study
    Signorelli, C.
    Calegari, M. A.
    Basso, M.
    Passardi, A.
    Lucchetti, J.
    Zurlo, I. V.
    Morelli, C.
    Dell'Aquila, E.
    Gemma, D.
    Emiliani, A.
    Arrivi, G.
    Zoratto, F.
    Chilelli, M. G.
    Morandi, M. G.
    Santamaria, F.
    Dettori, M.
    Cosimati, A.
    Saltarelli, R.
    Minelli, A.
    Ruggeri, E. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S35 - S35
  • [3] Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.
    Coutzac, Clelia
    Trouilloud, Isabelle
    Artru, Pascal
    Henriques, Julie
    Masson, Therese
    De La Fouchardiere, Christelle
    Doat, Solene
    Bouche, Olivier
    Coriat, Romain
    Saint, Angelique
    Moulin, Valerie
    Vernerey, Dewi
    Tougeron, David
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
    Ogata, Misato
    Kotaka, Masahito
    Ogata, Takatsugu
    Hatachi, Yukimasa
    Yasui, Hisateru
    Kato, Takeshi
    Tsuji, Akihito
    Satake, Hironaga
    PLOS ONE, 2020, 15 (06):
  • [5] Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience
    Signorelli, Carlo
    Gemma, Donatello
    Grande, Roberta
    De Marco, Salvatore
    Saltarelli, Rosa
    Morandi, Maria Grazia
    Spinelli, Gian Paolo
    Zoratto, Federica
    Sperduti, Isabella
    Chilelli, Mario Giovanni
    Ceribelli, Anna
    Ruggeri, Enzo Maria
    ANTICANCER RESEARCH, 2021, 41 (05) : 2553 - 2561
  • [6] Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.
    Signorelli, Carlo
    Schirripa, Marta
    Chilelli, Mario Giovanni
    Calegari, Maria Alessandra
    Basso, Michele
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Gemma, Donatello
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Arrivi, Giulia
    Morelli, Cristina
    Corsi, Domenico Cristiano
    Saltarelli, Rosa
    Morandi, Maria Grazia
    Zoratto, Federica
    Santamaria, Fiorenza
    Ruggeri, Enzo Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 45 - 45
  • [7] Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
    Patel, Anuj K.
    Abhyankar, Ritika
    Brais, Lauren K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Huynh, Lynn
    Yenikomshian, Mihran A.
    Ng, Kimmie
    Fuchs, Charles S.
    ONCOLOGIST, 2021, : e2161 - e2169
  • [8] Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study
    Kotaka, M.
    Ogata, M.
    Ogata, T.
    Hatachi, Y.
    Yasui, H.
    Kato, T.
    Tsuji, A.
    Satake, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
    Moriwaki, Toshikazu
    Fukuoka, Shota
    Taniguchi, Hiroya
    Takashima, Atsuo
    Kumekawa, Yusuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Esaki, Taito
    Makiyama, Chinatsu
    Denda, Tadamichi
    Satake, Hironaga
    Suto, Takeshi
    Sugimoto, Naotoshi
    Enomoto, Masanobu
    Ishikawa, Toshiaki
    Kashiwada, Tomomi
    Sugiyama, Masahiko
    Komatsu, Yoshito
    Okuyama, Hiroyuki
    Baba, Eishi
    Sakai, Daisuke
    Watanabe, Tomoki
    Tamura, Takao
    Yamashita, Kimihiro
    Gosho, Masahiko
    Shimada, Yasuhiro
    ONCOLOGIST, 2018, 23 (01): : 7 - 15
  • [10] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345